On 4/19/2017, Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed at $11.72 in last trading day. After noting the initial trading entry at $11.24, it reached to a day’s high of $12.04 and moved to a day’s low of $11.20. The recent daily volume was 1.37 million as contrast to it’s an average volume of 299.51 thousand.
The last close of the Karyopharm Therapeutics Inc. stock reflects that it traded up +3.82% from its 50-day moving average of $11.29. The stock traded above +17.18% to its 200-day MA of $10.00. Furthermore, it moved lower -19.89% from its 52-week high of $14.63 and +86.92% up from $6.27, which is 52-week low of the stock.
During the last month, KARYOPHARM THERAPEUTICS INC.’s (KPTI) has changed 9.84% and performed 37.88% over the last 6 months. The mean rating score for this stock is at 1.70. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 5.90% in recent month and observed Weekly Volatility of 5.92%.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Rayonier Inc. (NYSE:RYN) finalized the last transaction at value of $28.48, with a daily change of -0.42% or -0.12 points. The company maintained volume of 1.16 million shares. In past trading day, the stock hit the maximum price of $28.72 and touched to minimum value of $28.31. It has a market cap of $ 3.49B.
As of last trade close, the stock is trading downside -4.62% from its one year high of $29.86 and moved +16.86% upward from $24.37, which is one year low of the stock.
The stock traded below -0.14% from its 50-day moving average of $28.52. Furthermore, the stock moved up +3.45% to its 200-day MA of $ 27.53.
Rayonier Inc.’s (RYN) moved with shift of -0.94% in the past week. Over the last three months, the shares of the company have changed 5.39% and performed 12.63% over the last six months. The stock currently has Monthly Volatility of 1.29% and Weekly Volatility of 1.20%.
Rayonier Inc. operates as an investment arm of Rayonier TRS Operating Company. Rayonier, Inc. engages in the sale and development of real estate and timberland management, as well as in the production and sale of cellulose fibers in the United States, New Zealand, and Australia. The company operates in four segments: Timber, Real Estate, Performance Fibers, and Wood Products. Timber segment owns, leases, or manages timberlands and sells standing timber at auction to third parties, as well as sells delivered logs. Real Estate segment sells medium and large tracts of land with infrastructure. This segment holds development and rural properties primarily in the southeast United States. Performance Fibers segment manufactures cellulose specialties that are used principally in acetate textile fibers, cigarette filters, rigid packaging, LCD screens, photographic film, impact-resistant plastics, high-tenacity rayon yarn, pharmaceuticals, cosmetics, detergents, food casings, and food products; and absorbent materials that are used in disposable baby diapers, feminine hygiene products, incontinence pads, convalescent bed pads, industrial towels and wipes, and nonwoven fabrics. Wood Products segment primarily manufactures and sells dimension lumber used for residential and industrial construction applications. In addition, Rayonier involves in trading and exporting logs, lumber, and wood panel products. As of December 31, 2005, it owned, leased, or managed approximately 2.5 million acres of timberland and real estate. The company has a joint venture with RREEF Infrastructure to own and manage timber lands in New Zealand. Rayonier has elected to be treated as a real estate investment trust (REIT) for federal income tax purposes and would not be subject to federal income tax on its REIT income that it distributes to its shareholders. The company, formerly known as Rainier Pulp & Paper Company, was founded in 1926. Rayonier is headquartered in Jacksonville, Florida.